Background Whether non–vitamin K antagonist oral anticoagulants (NOAC s) are superior to
warfarin among Asians with nonvalvular atrial fibrillation remains unclear. Methods and …

Background Whether four direct oral anticoagulants (DOACs) are superior to warfarin in
Asian patients with nonvalvular atrial fibrillation (NVAF) remains unclear. Methods This …

Background—Vitamin K antagonist (VKA) therapy is increasingly being used for the
prevention of venous thromboembolism and stroke in atrial fibrillation. Bleeds are the major …

Background Liver cirrhotic patients with nonvalvular atrial fibrillation have been excluded
from randomized clinical studies regarding oral anticoagulants for stroke prevention …

Aims To evaluate the fracture risk among patients with atrial fibrillation (AF) treated with non-
vitamin K antagonist oral anticoagulants (NOACs) or warfarin. Methods and results We …

Background: Evidence about the association between types of oral anticoagulants and
hazards of diabetes complications is limited in patients with atrial fibrillation (AF) and …

Background Warfarin, a vitamin K antagonist, has been shown to affect bone mineral density
and cause osteoporosis. However, studies investigating the relationship between non …

Purpose Whether direct oral anticoagulants (DOACs) are more effective and safer than
warfarin among Asian patients with non-valvular atrial fibrillation (NVAF) undergoing dialysis …

Atrial fibrillation (AF), the most common cardiac arrhythmia, is associated with a significantly
increased risk of ischemic stroke, heart failure, and death. AF is a heterogenous disease in …

Background and Purpose: Data on clinical outcomes for nonvitamin K antagonist oral
anticoagulant (NOACs) and warfarin in patients with atrial fibrillation and cancer are limited …